Skip to main content
. Author manuscript; available in PMC: 2022 Jun 13.
Published in final edited form as: Int J Cancer. 2020 Jul 13;147(11):3250–3261. doi: 10.1002/ijc.33129

Figure 1:

Figure 1:

Mesenchymal associated transcriptomic signature (MATS) and its association with recurrence free survival in comparison to earlier published gene signatures and its ability to predict chemotherapy response (a) Kaplan-Meier survival curve derived from the LASSO cox regression model of MATS in the GSE39582 exploratory cohort. (b) Meta-analysis of the MATS classifier in predicting recurrence free survival using 9-independent microarray gene expression cohorts (c) Multivariate analysis of MATS in comparison to the earlier published gene expression signatures and subtypes